Skip to main content

This is a preprint.

It has not yet been peer reviewed by a journal.

The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed.

bioRxiv logoLink to bioRxiv
[Preprint]. 2026 Oct 20:2026.10.18.759991. [Version 1] doi: 10.64898/2026.10.18.759991

Olfactory neuroepithelium biomarker platform: a proof from Alzheimer’s disease

Koko Ishizuka, Guanqun Shang, Saba Malik, Carolyn Doty, Shrey Dave, Nicholas Rowan, Yukiko Lema, Andrew Lane, Akira Sawa
PMCID: PMC13738621  PMID: 42995972

Brief abstract

Unlike other diseases where target organs for biopsy are accessible, surrogate platforms are warranted for biomarkers of neuropsychiatric disorders due to the inaccessibility of the brain. We demonstrate a non-invasive platform combining a nasal soft-brush swab with single-cell Western blotting for neuron-specific protein analysis. Applied to Alzheimer’s disease targeting phosphorylated tau, this demonstrated superior diagnostic capacity compared with blood-based approaches, indicating that the olfactory neuroepithelium is a sensitive biomarker platform.

Full Text Availability

The license terms selected by the author(s) for this preprint version do not permit archiving in PMC. The full text is available from the preprint server.


Articles from bioRxiv are provided here courtesy of Cold Spring Harbor Laboratory Preprints

RESOURCES